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are complementary technologies. METHODS: We extracted
data for 5016 PCI patients with DES or non-DES, admitted
between April 24 and June 30, 2003 from the Solucient, LLC
ACTracker database—a proprietary database with detailed drug
information. Patients were identiﬁed as having received a
GPIIb/IIIa inhibitor if they received any of the following drugs:
abciximab, tiroﬁban, or eptiﬁbatide. The likelihood of a patient
with a DES receiving a GPIIb/IIIa inhibitor was modeled using
a logistic regression equation, adjusting for hospital and demo-
graphic characteristics, as well as whether the patient had an
acute myocardial infarction (AMI). RESULTS: Patients under-
going PCI with a DES were less likely than those undergoing PCI
with a non-DES to receive a GPIIb/IIIa inhibitor. However, the
results were not statistically signiﬁcant. (OR = 0.917, 95% CI
0.793, 1.061). CONCLUSIONS: Data from the time period just
after approval of drug-eluting stents does not show any statisti-
cally signiﬁcant difference between use of GPIIb/IIIa inhibitors
among PCI patients receiving DES and non-DES. However, the
lower use of GPIIb/IIIa inhibitors among DES patients in our
study may prove to be signiﬁcant once data from additional PCI
patients becomes available.
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Many patients are chronically treated with oral anticoagulants
to prevent thromboembolic events. These medications are life
saving but have a narrow therapeutic window, which can expose
these patients to life threatening events if the International 
Normalized Ratio (INR) is not kept within the therapeutic
window. High potential of drug-drug and drug-food interactions
adds to the complexity of achieving good anticoagulation
control, and knowledge of these interactions can assist in making
better therapeutic decisions. OBJECTIVE: To evaluate the
impact of clinical pharmacist intervention on anticoagulation
control in chronic patients. METHODS: Thirty-seven chronic
patients with uncontrolled anticoagulation were randomly iden-
tiﬁed from the data systems of Maccabi Health care Services. The
clinical pharmacist intervention consisted of meeting the family
practitioners in order to go over patient clinical charts, and
sending written recommendations regarding anticoagulation
control. Some of the patients were also invited to a personal
meeting with the clinical pharmacist for pharmaceutical guid-
ance, and were closely followed throughout the process.
Outcome analysis was based on comparison of the last two INR
results before and after the clinical pharmacist intervention,
according to target INRs, matching the speciﬁc indication for
anticoagulant therapy. RESULTS: Following the clinical phar-
macist intervention we observed a two-fold increase in the
number of patients with anticoagulation control: a 2.5 fold
increase in the number of patients with anticoagulation control
in the optimal range (INR between 2–3 for most of the indica-
tions and 3–4 for mechanical valve replacement), and a 1.8 fold
increase in the number of patients with anticoagulation control
in the tolerable range (INR between 1.8–4 for most of the 
indications and 2–4.25 for mechanical valve replacement). These
differences were statistically signiﬁcant (p = 0.018). CONCLU-
SION: These ﬁndings indicate that chronic patient’s anticoagu-
lation control strongly beneﬁts from clinical pharmacist
intervention. Further study is required to control for sponta-
neous patient improvement.
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OBJECTIVES: Individuals with hyperlipidemia are at risk for
CHD, hypertension and diabetes. This study examined the like-
lihood of receiving prescription therapy based on patient diag-
noses, demographics and other factors. METHODS: The study
design was retrospective covering January 2000–December
2002. It encompassed 15,000 electronic medical records from
primary care practices in eight States. Patients with lipoid disor-
ders were identiﬁed by ICD-9 diagnoses. Treatment patterns and
laboratory data were evaluated vs. NCEP ATP III Guidelines.
RESULTS: On average, 23.4% of patients eligible for treatment
according to the Guidelines were prescribed cholesterol lower-
ing drugs. Of those, 40.5% of patients (95% CI 39.6%–41.3%)
had prescription therapy without a hyperlipidemia diagnosis. In
each of these cases, one or more co-morbid diagnoses for CHD
risk were present. The likelihood of treatment for patients <45
years was 1.37 times lower (p < 0.001) than older patients in the
“ofﬁcial” risk age for CHD (55–64 years). The probability of
treatment for men was higher than for women (OR 1.11 p <
0.01). There was no signiﬁcant difference in treatment frequency
for Caucasians vs. blacks. The likelihood of treatment for
patients with documented hyperlipidemia was 3.86 times higher
than for those without a diagnosis (p < 0.0001). The likelihood
of treatment for patients with CHD was 1.6 times higher
(1.59–1.89) than for patients without. CONCLUSIONS: In
patients diagnosed with lipoid disorders and at risk for CHD,
the use of cholesterol lowering medication appears to be rela-
tively low compared to that recommended by the NCEP ATP III
Guidelines. In those patients who are prescribed cholesterol 
lowering medication without documented hyperlipidemia, the
presence of CHD risk factors appear to be a major considera-
tion. Possible reasons for a relatively low level of prescribing
include undocumented treatment by life style changes, lack of
awareness of NCEP guidelines by physicians, economic 
constraints, and/or other factors.
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OBJECTIVE: To examine the microvascular risk associated with
use of pioglitazone monotherapy versus insulin monotherapy 
in type 2 diabetes patients by retrospective analysis of the 
GE Medical Systems (GEMS) clinical database. METHODS:
Patients ≥18 years of age with a diagnosis of type 2 diabetes mel-
litus were included if on active treatment after 1999, and if no
microvascular events (one or more of neuropathy, nephropathy,
or retinopathy) were present at baseline. Only patients who were
initiated with pioglitazone or insulin as monotherapy were
